EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

vidarabine
adenine, 9b-D-arabinofuranosyl-

Supplier Sponsors

CAS Number: 5536-17-4Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:226-893-9
FDA UNII: 3XQD2MEW34
Nikkaji Web:J3.415K
Beilstein Number:0624881
MDL:MFCD00065471
XlogP3:-1.10 (est)
Molecular Weight:267.24541000
Formula:C10 H13 N5 O4
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:pharmaceuticals / chemical synthisis
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Appearance:white crystalline powder (est)
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 257.00 °C. @ 760.00 mm Hg
Boiling Point: 676.27 °C. @ 760.00 mm Hg (est)
Vapor Pressure:6.000000 mmHg @ 25.00 °C. (est)
Flash Point: 685.00 °F. TCC ( 362.80 °C. ) (est)
logP (o/w): -0.755 (est)
Soluble in:
 water, 8228 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
BOC Sciences
For experimental / research use only.
Adenine 9-b-D-arabinofuranoside (Vidarabine) > 99%
Odor: characteristic
Use: Arabinofuranosyl-adenine (ara-A) is an analog of adenosine with an antiviral property. It is often used as a prodrug that can be both substrate and inhibitor of DNA polymerase.
Carbosynth
For experimental / research use only.
9-(b-D-Arabinofuranosyl)adenine
George Uhe Company
9-B-D-Arabinofuranosyladenine Monohydrate
Glentham Life Sciences
Adenine 9-beta-D-arabinofuranoside
Santa Cruz Biotechnology
For experimental / research use only.
Vidarabine
Sigma-Aldrich: Sigma
For experimental / research use only.
Adenine 9-b-D-arabinofuranoside ≥99%
sds
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intravenous-human TDLo 300 ug/kg
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: ANOREXIA (HUMAN
Journal of Infectious Diseases. Vol. 133, Pg. A192, 1976.

intravenous-human TDLo 2 mg/kg
BEHAVIORAL: ATAXIA BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: TOXIC PSYCHOSIS
Journal of Infectious Diseases. Vol. 134, Pg. 75, 1976.

intraperitoneal-mouse LD50 3057 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

intravenous-mouse LD50 442 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

oral-mouse LD50 7800 ug/kg
"Kirk-Othmer Encyclopedia of Chemical Technology," 3rd ed., Grayson, M., and D. Eckroth, eds. New York, John Wiley & Sons, Inc., 1978Vol. 2, Pg. 962, 1978.

intraperitoneal-rat LD50 1476 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

intravenous-rat LD50 302 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

oral-rat LD50 > 5000 mg/kg
LIVER: OTHER CHANGES
Annals of the New York Academy of Sciences. Vol. 284, Pg. 6, 1977.

Dermal Toxicity:
subcutaneous-mouse LD50 5086 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

subcutaneous-rat LD50 8914 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
pharmaceuticals / chemical synthisis
Recommendation for vidarabine usage levels up to:
 not for fragrance use.
 
Recommendation for vidarabine flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA GENetic TOXicology:Search
EPA Substance Registry Services (TSCA):5536-17-4
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :21704
National Institute of Allergy and Infectious Diseases:Data
(2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Chemidplus:0005536174
EPA/NOAA CAMEO:hazardous materials
 
References:
 (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):21704
Pubchem (sid):134987129
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D06298
HMDB (The Human Metabolome Database):Search
MedlinePlusSupp:View
ChemSpider:View
Wikipedia:View
EFSA Update of results on the monitoring of furan levels in food:Read Report
EFSA Previous report: Results on the monitoring of furan levels in food:Read Report
EFSA Report of the CONTAM Panel on provisional findings on furan in food:Read Report
Formulations/Preparations:
•ophthalmic ointment 3% (equivalent to vidarabine, vira-a, parke-davis anhydrous 2.8%) •parenteral: concentrate, for injection, for iv infusion, 200 mgml (equivalent to 187.4 mg of anhydrous vidarabine per ml). vira-a (with benzethonium chloride and phosphate buffers), parke-davis •vidarabine not currently approved for use in the united states
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 adenine 9-b-D-arabinofuranoside
 adenine-9-b-D-arabinofuranoside
 adenine-b-D-arabinofuranoside
 adenine, 9-b-D-arabinofuranosyl-
 adenine, 9b-D-arabinofuranosyl-
6-amino-9-b-D-arabinofuranosylpurine
(2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
9-b-D-arabinofuranosyl-9H-purin-6-amine (9CI)
9-b-D-arabinofuranosyl-9H-purine-6-amine
9-b-D-arabinofuranosyladenine
9b-D-arabinofuranosyladenine
(+)-cyclaradine
 spongoadenosine
 vidarabin
 vidarabinum
 

Articles:

PubMed:Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.
PubMed:The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
PubMed:Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
PubMed:'Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption'.
PubMed:Drug repurposing for gastrointestinal stromal tumor.
PubMed:Rituximab in chronic lymphocytic leukemia.
PubMed:U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
PubMed:Ofatumumab in the treatment of chronic lymphocytic leukemia.
PubMed:Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.
PubMed:U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
PubMed:The odyssey of marine pharmaceuticals: a current pipeline perspective.
PubMed:Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes.
PubMed:Nelarabine: a new purine analog in the treatment of hematologic malignancies.
PubMed:Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
PubMed:Innovations in antineoplastic therapy.
PubMed:The bioavailability of oral fludarabine phosphate is unaffected by food.
PubMed:Emerging information on the use of rituximab in chronic lymphocytic leukemia.
PubMed:Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
PubMed:Late listeriosis after fludarabine plus prednisone treatment.
PubMed:Advances in therapy for hairy cell leukemia. A review.
PubMed:From the Food and Drug Administration.
PubMed:Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
PubMed:Purification and characterization of a novel nucleoside phosphorylase from a Klebsiella sp. and its use in the enzymatic production of adenine arabinoside.
PubMed:From the Food and Drug Administration.
PubMed:[The glomerulopathies of cirrhosis of the liver].
PubMed:Projections on the use of antiviral chemicals in animals.
PubMed:Vidarabine approved for herpes simplex virus encephalitis.
 
Notes:
a nucleoside antibiotic isolated from streptomyces antibioticus. it has some antineoplastic properties and has broad spectrum activity against dna viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia virus and varicella zoster virus.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy